Years Achievement

2nd USFDA Inspection of Formulation facility successfully completed with Zero 483’s in February 2018

Expansion of Oncology block to meet growing market demand


WHO-GMP Inspection of Formulation facility successfully completed in November 2017

5th USFDA Inspection of API facility successfully completed with Zero 483 observations in November 2017

3rd EUGMP inspection of API facility successfully completed in September 2017

1st USFDA Inspection of the Formulation facility successfully completed in July 2017


Launched Domestic Business Operation into super specialty segments like Immunology, Transplant Medicine & Chronic Kidney Disease segment.

Commissioned Formulation Manufacturing Facility at Valthera, Ahmedabad, India.

Granted FDA-India manufacturing licenses for FDF facility at Valthera, Ahmedabad, India


Established a state-of-the-art facilities to indigenously develop and manufacture Finished Drug Formulations at Valthera, Ahmedabad, Gujarat, India

Laid foundation stone for new Manufacturing facility at Valthera, Ahmedabad.

4th USFDA Inspection successfully completed at Dholka Site, Ahmedabad.


Filed submission for APIs DIL, China

Second EU GMP inspection conducted in May 2014

Commissioned Manufacturing Block No. 22.

2011 to 2013

Renewed Japanese AFM

3rd USFDA inspection in August 2012

Commissioned Block 20 & 21

Korean FDA inspection

Commissioned Block 19 for Oncology APIs with isolators to handle API and dedicated QC

Commissioned stand alone Manufacturing Blocks 17 & 18 for Lyophilization & Hydrogenation Respectively

CRAM activities initiated with major biopharmaceuticals company in areas of natural/semi-synthetic products

Commissioned Manufacturing Block 4A

First EU GMP inspection in April 2011

2008 to 2010

Existing share holders buyback Matrix/Mylan’s entire equity holding

Entry of Mycophenolate Mofetil & Tacrolimus in US generic market as a front runner

Commissioned Manufacturing Blocks 7, 8, 11, 12, 14, 15 & 16, enhancing fermentation & downstream capacities.

2nd USFDA inspection in March, 2008

2005 to 2007

Equity partnership by Matrix Laboratories

Fermentation capacity doubled

Commissioned Manufacturing Block 3, 4, 5 & 6

1st USFDA inspection for its Biotech facility

2001 to 2004

Commissioned Manufacturing Block 2 & started commercial production.

Initiated development & production of 1st Immunosuppressant

First DMF/ COS filed by Concord.

Scrapped small chemical unit & bought Biotech equipments & started production of Amidase Enzyme

1989 to 2000

Mr. Sudhir Vaid took over from DSM and named it CONCORD BIOTECH LIMITED

Taken over by DSM (formerly known as Max GB)

Promoted by Sanofi (formerly known as Hoechst)